Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 7/20 | 0.71 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.71 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.71 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.71 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.71 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.71 |
| ▸ | DRD3 | P35462 | 3/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.71 |
| ▸ | SCN1A | P35498 | 3/20 | 0.71 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.71 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.71 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.71 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.71 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.71 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.71 |
| ▸ | HRH2 | P25021 | 2/20 | 0.71 |
| ▸ | HTR2A | P28223 | 2/20 | 0.71 |
| ▸ | HTR2C | P28335 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diphenhydramine SCHEMBL28065480 | 0.90 | SLC6A2 (0.83) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| SCHEMBL15529408 | 0.86 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| SCHEMBL13302844 | 0.84 | SIGMAR1 (0.69) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| SCHEMBL11795338 | 0.84 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| SCHEMBL29807 | 0.84 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| SCHEMBL9173563 | 0.84 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| SCHEMBL147711 | 0.84 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| Diphenhydramine SCHEMBL12543374 | 0.83 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| Diphenhydramine SCHEMBL4064 | 0.83 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| SCHEMBL16590605 | 0.83 | SIGMAR1 (0.68) | SLC6A2SLC6A4SLC6A3LMNACHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150087697-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUSCLE PAIN | KANDULA MAHESH (IN) | 2015-03-26 | — | — | US | claimed |
| WO-2013167984-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUSCLE PAIN | KANDULA MAHESH (IN) | 2013-11-14 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-4132476-A1 | RHEOLOGICAL SOLID ORAL COMPOSITION | The Procter & Gamble Company (US) | 2023-02-15 | — | — | EP | disclosed |
| CN-109789101-A | Extend and alleviates dosage form | 宝洁公司 | 2019-05-21 | — | — | CN | disclosed |
| CN-109640956-A | Drug with improved taste and sensory experience | 宝洁公司 | 2019-04-16 | — | — | CN | disclosed |
| CN-109562137-A | Methods and compositions for treating conditions associated with abnormal inflammatory responses | 第波生物公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-104959052-B | The method for synthesizing membrane vesicle for preparing major diameter | 帕西拉制药有限公司 | 2018-07-13 | — | — | CN | disclosed |
| CN-105239181-B | Long filament, non-woven webs comprising activating agent and the method for preparing them | 宝洁公司 | 2018-05-22 | — | — | CN | disclosed |
| CN-104971672-B | Method for preparing major diameter synthesis membrane vesicle | 帕西拉制药有限公司 | 2018-01-02 | — | — | CN | disclosed |
| WO-2005037203-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005030132-A2 | THERAPEUTIC REGIMENS FOR ADMINISTERING DRUG COMBINATIONS | COMBINATORX, INCORPORATED (US) | 2005-04-07 | — | — | WO | disclosed |
| CN-1178699-C | Pharmaceutical Compsns. contg. compounds with activity for enhancement of absorption of active ingredients | — | 2004-12-08 | — | — | CN | disclosed |
| CN-1545408-A | Transdermal therapeutic system based on polyacrylate adhesive patches without functional groups | LTS��������ϵͳ�ɷݹ�˾ | 2004-11-10 | — | — | CN | disclosed |
| WO-2003030818-A2 | ACTIVE AGENTS USING LIPOSOME BEADS | SUVANPRAKORN PICHIT (TH) | 2003-04-17 | — | — | WO | disclosed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | disclosed |
| EP-1030659-A1 | (+)-EPHEDRINE AS A SYMPATHOMIMETIC DRUG | WARNER-LAMBERT COMPANY (US) | 2000-08-30 | — | — | EP | disclosed |
| WO-1999025328-A1 | (+)-EPHEDRINE AS A SYMPATHOMIMETIC DRUG | WARNER-LAMBERT COMPANY (US) | 1999-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087697-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUSCLE PAIN | TNNC1, MUSK, OPRK1 | SLC6A2 223/4885SLC6A4 106/4885SLC6A3 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.